11/26
08:30 am
fblg
FibroBiologics Announces Payoff of Outstanding Debt
Low
Report
FibroBiologics Announces Payoff of Outstanding Debt
11/25
04:56 pm
fblg
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
11/25
04:05 pm
fblg
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Low
Report
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/24
09:00 am
fblg
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
High
Report
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/20
08:22 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
11/20
08:00 am
fblg
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
Medium
Report
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
11/19
07:03 pm
fblg
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Low
Report
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/19
08:36 am
fblg
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
High
Report
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/5
07:19 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/3
08:03 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
10/31
04:53 pm
fblg
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
10/31
04:30 pm
fblg
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/24
08:30 am
fblg
FibroBiologics to Present at Bio-Europe 2025
Medium
Report
FibroBiologics to Present at Bio-Europe 2025
10/14
08:30 am
fblg
FibroBiologics to Present at the 2025 ThinkEquity Conference
Low
Report
FibroBiologics to Present at the 2025 ThinkEquity Conference
9/23
08:30 am
fblg
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
Low
Report
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
9/12
08:44 am
fblg
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies [Yahoo! Finance]
Low
Report
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies [Yahoo! Finance]
9/12
08:30 am
fblg
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
High
Report
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
9/12
08:03 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/11
08:48 am
fblg
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment [Yahoo! Finance]
Low
Report
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment [Yahoo! Finance]
9/11
08:30 am
fblg
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
Low
Report
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
9/10
11:38 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Low
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
9/10
08:52 am
fblg
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies [Yahoo! Finance]
Low
Report
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies [Yahoo! Finance]
9/10
08:30 am
fblg
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
Medium
Report
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies